Special Issue "SARS-CoV-2: Vaccines in the Pandemic Era"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 1477

Special Issue Editors

Yale School of Medicine, Yale University, New Haven, CT 06510, USA
Interests: viral innate immune response; vaccine; single-cell sequence

E-Mail Website
Guest Editor Assistant
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA
Interests: viral innate immune response; vaccine; RNA modification

Special Issue Information

Dear Colleagues,

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), which emerged in December 2019 in Wuhan, China. Symptoms of SARS-CoV-2 infection are primarily respiratory, although an increasing number of other syndromes such as cognitive deficits have been reported. As of 17 November 2022, the COVID-19 pandemic has resulted in more than 636 million infections with over 6.6 million deaths (https://coronavirus.jhu.edu/). Since the pandemic, multiple SARS-CoV-2 vaccine platforms have been successfully developed for COVID-19, including messenger RNA (mRNA), inactivated virus, adenovirus vectors (Ad26.COV2.S and ChAdOx1), and spike (S) protein subunit vaccine. These vaccines demonstrate high efficacy against SARS-CoV-2 and dramatical reduction in viral transmission, hospitalization, and deaths following two intramuscular injections. However, an increasing number of new SARS-CoV-2 variants of concern (VOCs) have emerged, including the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and recently dominant circulating Omicron variant. These emerging SARS-CoV-2 VOCs have significantly impaired the effectiveness of current SARS-CoV-2 vaccines.

To achieve a more extensive understanding of recent scientific knowledge in SARS-CoV-2 vaccines, this Special issue focuses on SARS-CoV-2 vaccine development. We invite you contribute original research and reviews papers on SARS-CoV-2. Topics of interest range from SARS-CoV-2 vaccine development to preclinical research and clinical evaluation.

Dr. Weihong Gu
Guest Editor
Yuexiu Zhang
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • SARS-CoV-2
  • vaccine design
  • vaccine development
  • vaccination
  • immune responses

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


17 pages, 1730 KiB  
Booster Dose Vaccination and Dynamics of COVID-19 Pandemic in the Fifth Wave: An Efficient and Simple Mathematical Model for Disease Progression
Vaccines 2023, 11(3), 589; https://doi.org/10.3390/vaccines11030589 - 03 Mar 2023
Viewed by 1219
Background: Mathematical studies exploring the impact of booster vaccine doses on the recent COVID-19 waves are scarce, leading to ambiguity regarding the significance of booster doses. Methods: A mathematical model with seven compartments was used to determine the basic and effective reproduction numbers [...] Read more.
Background: Mathematical studies exploring the impact of booster vaccine doses on the recent COVID-19 waves are scarce, leading to ambiguity regarding the significance of booster doses. Methods: A mathematical model with seven compartments was used to determine the basic and effective reproduction numbers and the proportion of infected people during the fifth wave of COVID-19. Using the next-generation matrix, we computed the effective reproduction parameter, Rt. Results: During the fifth COVID-19 wave, the basic reproductive number in Thailand was calculated to be R0= 1.018691. Analytical analysis of the model revealed both local and global stability of the disease-free equilibrium and the presence of an endemic equilibrium. A dose-dependent decrease in the percentage of infected individuals was observed in the vaccinated population. The simulation results matched the real-world data of the infected patients, establishing the suitability of the model. Furthermore, our analysis suggested that people who had received vaccinations had a better recovery rate and that the death rate was the lowest among those who received the booster dose. The booster dose reduced the effective reproduction number over time, suggesting a vaccine efficacy rate of 0.92. Conclusion: Our study employed a rigorous analytical approach to accurately describe the dynamics of the COVID-19 fifth wave in Thailand. Our findings demonstrated that administering a booster dose can significantly increase the vaccine efficacy rate, resulting in a lower effective reproduction number and a reduction in the number of infected individuals. These results have important implications for public health policymaking, as they provide useful information for the more effective forecasting of the pandemic and improving the efficiency of public health interventions. Moreover, our study contributes to the ongoing discourse on the effectiveness of booster doses in mitigating the impact of the COVID-19 pandemic. Essentially, our study suggests that administering a booster dose can substantially reduce the spread of the virus, supporting the case for widespread booster dose campaigns. Full article
(This article belongs to the Special Issue SARS-CoV-2: Vaccines in the Pandemic Era)
Show Figures

Figure 1

Back to TopTop